This document discusses drug development for rare diseases like Duchenne Muscular Dystrophy (DMD) from an academic and patient perspective. It outlines the involvement of patient communities, importance of timely tool development, and involving all stakeholders. It discusses the development of exon skipping therapy for DMD including preclinical research in cells and mice, early clinical trials, and challenges with placebo-controlled trials due to limited natural history data and outcome measures. Key lessons are the need for natural history data, developing outcome measures with patients, and involving all stakeholders from an early stage.
Presentation by Rochelle Lowe of Great Ormond Street Hospital for Children NHS Foundation Trust at the London Cancer Children, Teenager and Young Adults Study Day, held on 25 July 2013.
Presentation by Rochelle Lowe of Great Ormond Street Hospital for Children NHS Foundation Trust at the London Cancer Children, Teenager and Young Adults Study Day, held on 25 July 2013.
Comparative evaluation of 2g single dose versus conventional dose azithromycin in uncomplicated skin and skin structure infections. Indian Journal Of Pharmacology. August 2015;Vol. 47; Issue 4
Syringe driver medications: A study of combinations and clinical stability
Derryn Gargiulo, Jeff Harriso, Emma Griffiths, Bruce Foggo, Lauren Doherty, Sana Khan, Kate Kilpatrick, Guangda Ma, Caitlin Renouf, Susan Wilson
This webinar will tell you what you need to know about clinical trials, their history, and help you prepare for a trial. If you’re currently considering participating in a clinical trial, we hope that this webinar helps to answer many of your questions.
In the presentation you'll learn the difference between different types of clinical trial and the design and purpose of clinical trials, and you'll get an inside look at the approval process.
The webinar was hosted by Dawn Richards, Director of Patient and Public Engagement at Clinical Trials Ontario and featured a panel of patients, James Davidson, Eric Pitters and Kathie LaForge.
Medical Related information reconciliation when a patient sees many providers or transfers between health facilities is challenging. Lack of updated and correct information is a key concern for patient safety during a health and illness trajectory [1]. Errors, near misses and adverse medication events are too common, particularly whne transfers between hospitals, nursing home and home are frequent, or engagement of multiple specialties is common [2]. Lack of effective informatics support can be harmful to a person’s health, leading to suffering, increased use of health care resources and increased costs.
As a case for interactive discussion, we have chosen information exchanges related to medication, prescription-based as well as over the counter drugs. This challenging chain of activities includes: (a) prescribing on paper or electronically by several medical specialists, (b) transcribing by sending and interpreting prescriptions in the pharmacy, (c) dispensing medication by brand name or generic substitution, (d) acquiring over the counter medication, (e) administering medication as a user, and (f) observing effects and side-effects. The risk of missing information leading to mistakes in the chain of activities in medication management is likely to increase as complex medication regimes become common due to demographic developments, co-morbidities or more personalized treatment. Potentials in patient activation and relevant informatics tools for medication reconciliation need further exploration.
Anne MOEN Institute for Health and Society, Faculty of Medicine, University of Oslo, NORWAY
Catherine CHRONAKI HL7 Foundation, Brussels, BELGIUM
Christian NØHR, Aalborg University, DENMARK
Line Helen LINSTAD Norwegian Center for eHealth Research, Tromsø, NORWAY
Petter HURLEN Akershus University Hospital, NORWAY
ICN Victoria presents Dr Dashiell Gantner, research fellow at the Monash University in Melbourne. Here he talks about translating ICU research into clinical practice.
Comparative evaluation of 2g single dose versus conventional dose azithromycin in uncomplicated skin and skin structure infections. Indian Journal Of Pharmacology. August 2015;Vol. 47; Issue 4
Syringe driver medications: A study of combinations and clinical stability
Derryn Gargiulo, Jeff Harriso, Emma Griffiths, Bruce Foggo, Lauren Doherty, Sana Khan, Kate Kilpatrick, Guangda Ma, Caitlin Renouf, Susan Wilson
This webinar will tell you what you need to know about clinical trials, their history, and help you prepare for a trial. If you’re currently considering participating in a clinical trial, we hope that this webinar helps to answer many of your questions.
In the presentation you'll learn the difference between different types of clinical trial and the design and purpose of clinical trials, and you'll get an inside look at the approval process.
The webinar was hosted by Dawn Richards, Director of Patient and Public Engagement at Clinical Trials Ontario and featured a panel of patients, James Davidson, Eric Pitters and Kathie LaForge.
Medical Related information reconciliation when a patient sees many providers or transfers between health facilities is challenging. Lack of updated and correct information is a key concern for patient safety during a health and illness trajectory [1]. Errors, near misses and adverse medication events are too common, particularly whne transfers between hospitals, nursing home and home are frequent, or engagement of multiple specialties is common [2]. Lack of effective informatics support can be harmful to a person’s health, leading to suffering, increased use of health care resources and increased costs.
As a case for interactive discussion, we have chosen information exchanges related to medication, prescription-based as well as over the counter drugs. This challenging chain of activities includes: (a) prescribing on paper or electronically by several medical specialists, (b) transcribing by sending and interpreting prescriptions in the pharmacy, (c) dispensing medication by brand name or generic substitution, (d) acquiring over the counter medication, (e) administering medication as a user, and (f) observing effects and side-effects. The risk of missing information leading to mistakes in the chain of activities in medication management is likely to increase as complex medication regimes become common due to demographic developments, co-morbidities or more personalized treatment. Potentials in patient activation and relevant informatics tools for medication reconciliation need further exploration.
Anne MOEN Institute for Health and Society, Faculty of Medicine, University of Oslo, NORWAY
Catherine CHRONAKI HL7 Foundation, Brussels, BELGIUM
Christian NØHR, Aalborg University, DENMARK
Line Helen LINSTAD Norwegian Center for eHealth Research, Tromsø, NORWAY
Petter HURLEN Akershus University Hospital, NORWAY
ICN Victoria presents Dr Dashiell Gantner, research fellow at the Monash University in Melbourne. Here he talks about translating ICU research into clinical practice.
Day 2: Innovation to optimise therapeutic options for prevention and treatmen...KTN
The focus of this day is to explore unmet clinical needs in the effective treatment and therapy of patients with multiple long term conditions. Such patients have been historically excluded from clinical trials and also suffer from the burden of polypharmacy complications that affect quality of life. Innovation that supports a more holistic and personalised intervention, that applies patient stratification and pharmacogenomics, could dramatically improve health outcomes for diverse patient groups.
Nw biotech fundamentals day 2 session 4 medical devices and diagnosticsNicholas Weston Lawyers
In this presentation:
• Definition of Medical devices and Diagnostics
• The stages of an R&D project
• The state of the art
• Regulatory nuances
• Future trends
• Challenges and opportunities
• Case studies and examples
2015 04-13 Pharma Nutrition 2015 Philadelphia Alain van GoolAlain van Gool
Keynote lecture at the Pharma-Nutrition 2015 conference, outline global paradigm shifts and activities in pharma, personalized healthcare and pharmanutrition combination therapies.
Big Data and Genomic Medicine by Corey NislowKnome_Inc
View the webinar at: http://www.knome.com/webinar-big-data-genomic-medicine. This presentation covers an overview of genomic medicine, requirements and challenges of next-generation sequencing, bottlenecks to broader healthcare adoption, and why “we want to sequence everyone.”
The MemTrax team has been researching and developing innovative ways to investigate and measure the human brain.
Our vast network of talent has led the Alzheimer's disease and dementia research community for years.
The most well funded researchers in the world use MemTrax because it is simple, fun, and reliable.
he idea that being proactive and preventative about your cognition and brain health is critical for a long happy life.
By using our free online memory test users are able to take a quick interactive cognitive test and watch their results on special graphs and charts we have developed.
MemTrax is a family founded business created to motivate and inspire people in taking a proactive and preventative approach to caring for their brain health. Our mission is to continue to develop innovative cognitive assessments that are fun and repeatable while advancing research to better understand the human brain
Please reach out if you might have any questions.
Pharmacology Forever ! has been set as a meeting in recognition of Frits Peters tremendous involvement in pharmacology. This presentation discusses latest drug development methods and is illustrated by exemple of new drugs and target in oncology.
Phenomics assisted breeding in crop improvementIshaGoswami9
As the population is increasing and will reach about 9 billion upto 2050. Also due to climate change, it is difficult to meet the food requirement of such a large population. Facing the challenges presented by resource shortages, climate
change, and increasing global population, crop yield and quality need to be improved in a sustainable way over the coming decades. Genetic improvement by breeding is the best way to increase crop productivity. With the rapid progression of functional
genomics, an increasing number of crop genomes have been sequenced and dozens of genes influencing key agronomic traits have been identified. However, current genome sequence information has not been adequately exploited for understanding
the complex characteristics of multiple gene, owing to a lack of crop phenotypic data. Efficient, automatic, and accurate technologies and platforms that can capture phenotypic data that can
be linked to genomics information for crop improvement at all growth stages have become as important as genotyping. Thus,
high-throughput phenotyping has become the major bottleneck restricting crop breeding. Plant phenomics has been defined as the high-throughput, accurate acquisition and analysis of multi-dimensional phenotypes
during crop growing stages at the organism level, including the cell, tissue, organ, individual plant, plot, and field levels. With the rapid development of novel sensors, imaging technology,
and analysis methods, numerous infrastructure platforms have been developed for phenotyping.
Salas, V. (2024) "John of St. Thomas (Poinsot) on the Science of Sacred Theol...Studia Poinsotiana
I Introduction
II Subalternation and Theology
III Theology and Dogmatic Declarations
IV The Mixed Principles of Theology
V Virtual Revelation: The Unity of Theology
VI Theology as a Natural Science
VII Theology’s Certitude
VIII Conclusion
Notes
Bibliography
All the contents are fully attributable to the author, Doctor Victor Salas. Should you wish to get this text republished, get in touch with the author or the editorial committee of the Studia Poinsotiana. Insofar as possible, we will be happy to broker your contact.
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...University of Maribor
Slides from talk:
Aleš Zamuda: Remote Sensing and Computational, Evolutionary, Supercomputing, and Intelligent Systems.
11th International Conference on Electrical, Electronics and Computer Engineering (IcETRAN), Niš, 3-6 June 2024
Inter-Society Networking Panel GRSS/MTT-S/CIS Panel Session: Promoting Connection and Cooperation
https://www.etran.rs/2024/en/home-english/
Toxic effects of heavy metals : Lead and Arsenicsanjana502982
Heavy metals are naturally occuring metallic chemical elements that have relatively high density, and are toxic at even low concentrations. All toxic metals are termed as heavy metals irrespective of their atomic mass and density, eg. arsenic, lead, mercury, cadmium, thallium, chromium, etc.
Seminar of U.V. Spectroscopy by SAMIR PANDASAMIR PANDA
Spectroscopy is a branch of science dealing the study of interaction of electromagnetic radiation with matter.
Ultraviolet-visible spectroscopy refers to absorption spectroscopy or reflect spectroscopy in the UV-VIS spectral region.
Ultraviolet-visible spectroscopy is an analytical method that can measure the amount of light received by the analyte.
The ability to recreate computational results with minimal effort and actionable metrics provides a solid foundation for scientific research and software development. When people can replicate an analysis at the touch of a button using open-source software, open data, and methods to assess and compare proposals, it significantly eases verification of results, engagement with a diverse range of contributors, and progress. However, we have yet to fully achieve this; there are still many sociotechnical frictions.
Inspired by David Donoho's vision, this talk aims to revisit the three crucial pillars of frictionless reproducibility (data sharing, code sharing, and competitive challenges) with the perspective of deep software variability.
Our observation is that multiple layers — hardware, operating systems, third-party libraries, software versions, input data, compile-time options, and parameters — are subject to variability that exacerbates frictions but is also essential for achieving robust, generalizable results and fostering innovation. I will first review the literature, providing evidence of how the complex variability interactions across these layers affect qualitative and quantitative software properties, thereby complicating the reproduction and replication of scientific studies in various fields.
I will then present some software engineering and AI techniques that can support the strategic exploration of variability spaces. These include the use of abstractions and models (e.g., feature models), sampling strategies (e.g., uniform, random), cost-effective measurements (e.g., incremental build of software configurations), and dimensionality reduction methods (e.g., transfer learning, feature selection, software debloating).
I will finally argue that deep variability is both the problem and solution of frictionless reproducibility, calling the software science community to develop new methods and tools to manage variability and foster reproducibility in software systems.
Exposé invité Journées Nationales du GDR GPL 2024
Professional air quality monitoring systems provide immediate, on-site data for analysis, compliance, and decision-making.
Monitor common gases, weather parameters, particulates.
This presentation explores a brief idea about the structural and functional attributes of nucleotides, the structure and function of genetic materials along with the impact of UV rays and pH upon them.
1. Academic and patient representatives
perspective on drug development for
rare diseases
Annemieke Aartsma-Rus & Elizabeth Vroom
June 2018
2. Annemieke Aartsma-RusDepartment of Human Genetics2
Outline talk
Use therapy development for DMD as a showcase
• Patient community involvement
• The need for timely tool development
• The importance of involving all stakeholders
• The importance of good communiciation
• Bilateral education trilateral education
• Can we learn from our mistakes?
7. Annemieke Aartsma-RusDepartment of Human Genetics7
Step 1: Fundamental research ($$)
• DMD patients lack dystrophin protein
• BMD patients have altered dystrophins
• Acts as shock absorber
• Connects muscle cytoskeleton to connective
tissue
• Functional domains located at beginning and end
16. Annemieke Aartsma-RusDepartment of Human Genetics 16
AONs
• Modified pieces of RNA/DNA
• Many different modifications possible
• We use 2’-O-methyl phosphorothioate
• Transfection needed in cell culture
• Saline injection possible in mouse
17. Annemieke Aartsma-RusDepartment of Human Genetics17
Step 1: DMD cells start making dystrophin
5247
525147
M NT 51 -RT HC0h 4h 8h 16h24h48h
NT 48 post transfection
MANDYS1 DYS2MANDYS1
18. Annemieke Aartsma-RusDepartment of Human Genetics18
Mutation specific approach
hotspot
Dystroglycan domain
Exon All mutations Deletions
51 14% 21%
45 9.0% 13%
53 8.1% 12%
44 7.6% 11%
50 3.8% 5.6%
43 3.1% 4.5%
8 2.0% 2.9%
Bladen et al, Hum Mut 2015
23. Annemieke Aartsma-RusDepartment of Human Genetics23
Step 3: mouse models
• No animal model is perfect – that does not mean
they are not useful
• Spontaneous mutation in mouse dystrophin
• No dystrophin production
• Dystrophic muscles
• Milder phenotype
• Test systemic delivery
24. Annemieke Aartsma-RusDepartment of Human Genetics 24
Considerations for AON delivery
• AONs very small (~8-12 kDa)
• Filtered out by kidney
• Phosphorothiate modification
• Serum protein binding
• Less clearance by kidney
• Uptake by liver
• Uptake muscle poor, heart very poor
25. Annemieke Aartsma-RusDepartment of Human Genetics25
Systemic studies in mdx mice
WT Mice
Mdx Mice
AON levels in muscle and Liver
Gastrocn.
26. Annemieke Aartsma-RusDepartment of Human Genetics26
Step 4: Systemic efficacy trials
How are drugs approved?
•For rare diseases European Medicines Agency (EMA)
approves drugs
•Regulators base approval on benefit/risk analysis
•Need to show ‘clincial benefit’ for patients
•Need tools
• Outcome measures
• Natural history data
27. Annemieke Aartsma-RusDepartment of Human Genetics 27
Ready for trials????
• Limited natural history data
• Limited outcome measures
•No biomarkers
• Preclinical studies not standardized
• Rare disease multiple trials sites needed?
• Care standards
• Trial sites where?
• Personalized approach
• Registries needed
28. Annemieke Aartsma-RusDepartment of Human Genetics 28
Infrastructure needed for clinical trials
• Natural history data
• Outcome measures
• Biomarkers
• Rare disease multiple trials sites needed
• Care standards
• Expert centers for DMD
• Personalized approach
• Registries to identify eligible patients
29. 29|TREAT-NMD
BioBank
Patient
Registries
Care & Trial
Site Registry
Outcome
Measures
Standards of
Diagnosis &
Care
TACT
Website &
Communications
Joint
Research
Standard
Operating
Procedures
Three year
work plan
www.treat-nmd.eu
Action Plan
3 year plan
Milestone-driven
approach
Maintains network
momentum & establish
new goals
Website &
Communication
Extensive website
250,000 annual page hits
70,000 visitors annually
Monthly newsletter sent
to 3,500 recipients
Proven communication
platform
Secretariat - Kate Bushby
Volker Straub
Funding – EC (operating
grant)
TACT
TREAT-NMD Advisory
Committee for
Therapeutics,
Expert multidisciplinary
body
Independent and objective
guidance on advancing
new therapies for
neuromuscular diseases
Chair – Dominic Wells
Funding - US (Dept of
Defense)
Joint research
Regular meetings to
consolidate efforts and
jointly tackle common
problems
Topics based on necessity,
hosting to be rotated
between partners
Leads - Eric Hoffman
Annemieke Aartsma-Rus
Filippo Buccella
Funding - COST
SOPs
Unified experimental
protocols improve the
comparability of studies
Drawn up by a group of
independent researchers
(listed in each protocol)
Approx 40 sops updated
regularly
EuroBioBank
Unique network of 18
members
Stores & distributes
440,000 quality DNA, cell
and tissue samples
Leads - Marina Mora
Lucia Monaco
Marco Crimi
Funding - Fondazione
Telethon
Patient Registries
Standardized genetic &
clinical core data for trial
recruitment
Interface can vary
between countries whilst
still able to share core data
Ethical & governance best
practice
>10,000 DMD patients
across 30 countries
Leads - Jan Verschuuren
Hugh Dawkins
Funding - AFM & EC
(operating grant)
Care & Trial Site
Registry
Information about each
registered trial site kept in
one location for ease of
comparison
Addresses organisational
difficulties of identifying
appropriate sites when
setting up a trial
Coordinated by University
Medical Center Freiburg
Outcome measures
Tests to decide whether
treatment being tested in
a trial is having any effect
Vital to use the correct
outcome measure to
prove if a treatment works
Working to harmonise the
use of most appropriate
outcome measures for
different diseases
Lead - Eugenio Mercuri
Funding - Telethon & Parent
Organizations
Standards of
Diagnosis & Care
International consensus
publication recommended
standards of care
DMD-SMA-CMD-LGMD
Family guides
in 25 different languages
translations verified
Printed booklets or
download from
website
Leads - Thomas Sejersen
Kathy North
2007-2011
EU funded Network
2012 onwards
Alliance funded
through multiple
streams with global
partners & membership
Governance
Chair – Kevin Flannigan
Vice Chair – Jan Kirschner
Executive Committee
Supported by academic
advisory board (“task force”)
of NMD leaders
33. Interactions with Industry
‘Early access to medicines in Europe:
Compassionate use to become a reality’
Eurordis
‘Code of Practice between patient
organisations and the healtcare
industry’
Eurordis
Community Advisory Board
Eurordis
34. Meanwhile: trials were initiated
Annemieke Aartsma-Rus
• Dose escalating study (0.5 – 6 mg/kg/week for 4
weeks (April 2008)
• Dystrophin restored in 10/12 patients
• All patients then enrolled in an open label
extension study (July 2009)
• 6 mg/kg drisapersen per week for 72 weeks
• Then 8 weeks break
• Then cycles of 8 weekly doses, 4 week break
• Treated for almost 4 years
Goemans et al, NEJM 2011, 364: 1513-22
35. 6 Minute walk test
• Global measure of function arising from cardio respiratory field
• Captures clinically meaningful aspect of day-to-day life of ambulant DMD
• Precedent of regulatory approval obtained based on 6MWD in NMD
• Modified, standardized procedure described for DMD (C.McDonald, 2010)I
• Is currently used as (primary) endpoint in therapeutic trials
38. Open Label Extenion Trial Drisapersen
Annemieke Aartsma-Rus
• Side effects observed
• Local injection site reactions
• Proteinuria (reversible during breaks)
• Thrombocytopenia seen for some patients
• Seen in all phase 2/3 trials drisapersen
• 6 minute walk distance maintained for >3.5 years
in 8/10 ambulant patients
• Very encouraging results but no placebo group
39. Placebo-controlled trial drisapersen
Annemieke Aartsma-Rus
• 54 patients
• Early stage of disease (able to rise from floor in < 7 sec)
• Steroid treated
• Treatment for 48 weeks with 6 mg/kg drisapersen
subcutaneous or placebo
• Weekly injections (18 patients)
• Intermittent regimen (17 patients)
• Placebo (18 patients)
40. Primary Endpoint: Change from Baseline (95% CI) in 6MWD
(m), ITT Population
Visit Comparison Treatment Difference P-value
Week 25 (Primary) Weekly vs Placebo 35.09 0.014
Intermittent vs Placebo 3.51 0.801
Week 49 (Secondary) Weekly vs Placebo 35.84 0.051
Intermittent vs Placebo 27.08 0.147
41. Placebo-controlled trial drisapersen
Annemieke Aartsma-Rus
• 51 patients
• Early stage of disease (rise from floor <15 seconds)
• Steroid treated
• Treatment for 24 weeks with 3 or 6 mg/kg
drisapersen subcutaneous or placebo
• 24 week wash out
42.
43. Placebo study drisapersen
Annemieke Aartsma-Rus
• Phase 3 (48 weeks)
• Patients 5-16 years old (186)
• Global study
• 6 mg/kg/week or placebo
44. Primary Endpoint: 6MWD
Adjusted Mean Change from Baseline (95% CI) in 6MWD (m) – Primary MMRM analysis
ITT Population
Treatment difference = 10.3m,
p-value = 0.415 at Week 48
Curves offset for visualization
4.7m 4.8m 1.8m
- 52.7 m
- 42.3 m
48. Annemieke Aartsma-RusDepartment of Human Genetics48
In hindsight
• Information too limited to allow set up ideal trial
• Limited information on 6MWT
• Variation
• Progression in different age ranges
• Power calculations impossible
• Selection of ideal cohort impossible
• Difficult to pick up minor treatment effect
49. Annemieke Aartsma-RusDepartment of Human Genetics49
Is this the end?
• Phase 3 population more advanced disease
• See more response in younger patients
• See more response in early stage patients
• Open label studies: effect clearer after 2 years
• Applied for FDA approval: not granted
• EMA application withdrawn
• Limited benefit vs side effects
• Exon 44, 45 and 53 skipping programms stopped
• Focus on next generation AONs
50. Annemieke Aartsma-RusDepartment of Human Genetics50
Trilateral education
• Regulators are no experts in any rare disease
• DMD field no expert in regulatory affairs
• Stakeholder meetings organized to learn each
others language and perspective and plan for
future
• Patients/parents
• Academics
• Regulators
• Industry
51. EMA
‘Drugs are approved on data not on emotions’
Have arguments included in the discussion
No drama
Patients included in scientific committees
More (real life) data needed
Strict conflict of interest rules
54. EMA - CHMP
Signed by 65 Muscle organisations and Eurordis
Collective letter (incl data) for example on patient preferences
Members from all countries
Input via patient representatives in committees
Distributed Among all members by EMA
62. Annemieke Aartsma-RusDepartment of Human Genetics62
Current situation
• No functional data available yet
• Approval based on minute increases in dystrophin
• Clear room for improvement
• Evaluation EMA pending
63. Annemieke Aartsma-RusDepartment of Human Genetics63
Lessons learned by the field
• Have natural history data available (especially for
your outcome measures)
• Suboptimal trial design can lead to false negative
results (especially for low effective drugs)
• Develop outcome measures in parallel with
therapeutic approach and involve patients
• Involve all stakeholders from an early stage
• Learn each other’s language